Targeted therapy has been proven to greatly improve the treatment effect of tumor patients, and targeted therapy is gradually becoming a hot spot in the field of anti-tumor therapy. In terms of mechanism of action, targeted drugs are used to stop the growth of cancer cells through specific molecular targets that are necessary for cancer occurrence and tumor growth, and it has its specific indications for the population, not every tumor patient has the opportunity to undergo targeted therapy. With the continuous research and development of targeted therapy drugs and their wide clinical application, the treatment mode of more tumor patients has converged to that of chronic diseases such as hypertension, diabetes and coronary heart disease, where taking drugs at home can both effectively control tumors and achieve survival with tumors, even without dying from cancer. Although targeted drugs are effective, they are not effective for everyone because different patients carry different mutated genes, and the same drug that is effective for “Zhang San” may not work at all for “Li Si”. The mutated genes in different patients may be different, so genetic testing should be used to screen for the corresponding target drug and to make a general assessment of the expected efficacy of the drug before using it. It is highly undesirable for many patients in China to try targeted drugs “blindly”. Genetic mutations and targeted drugs must match in order for patients to benefit, otherwise it may be counterproductive. Genetic testing is recommended for patients with mid- to late-stage tumors, especially for patients with mid- to late-stage non-small cell lung cancer. To date, the number of lung cancer patients known to have positive significant gene mutations has reached 70% of the total number of non-small cell lung cancer patients. This means that 70% of non-small cell lung cancer patients will be able to find the corresponding targeted drugs through genetic testing to extend their survival cycle and improve their quality of life.